Humana lacks evidence for US price-fixing allegations, Taro says
MLex Summary: Evidence obtained by Humana in antitrust litigation against Taro Pharmaceutical reflects "at most, ordinary parent-subsidiary oversight and executive supervision within a multinational enterprise," Taro told a Pennsylvania federal judge....To view the full article, register now.
Already a subscriber? Click here to view full article